ReviewNature reviews. Rheumatology2013
Advances from clinical trials in juvenile idiopathic arthritis.
Review in Nature reviews. Rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- How can innovative trials in juvenile idiopathic arthritis serve the unmet needs of patients?Arthritis research & therapy · 2026Review
- The challenges and opportunities for equitable global access to medications for paediatric rheumatology in low-to middle-income countries: a review on behalf of the Paediatric Global Task Force for Musculoskeletal Health.Arthritis research & therapy · 2026Review
- Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Adoption of new treatment options in non-systemic juvenile idiopathic arthritis (JIA) in clinical practice.Pediatric rheumatology online journal · 2025Article
- Forecasting Achievement of Inactive Disease in Juvenile Idiopathic Arthritis with Artificial Intelligence.Children (Basel, Switzerland) · 2025Article
- Frequency of remission achievement in the pre-treat-to-target decade in juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2025Article
- Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry.Rheumatology (Oxford, England) · 2024Observational
- Presentation of enthesitis-related arthritis and juvenile-onset spondyloarthritis: a cross-sectional study in a pediatric and adult clinic.Advances in rheumatology (London, England) · 2024Article
- Treat-to-Target in Pediatric Rheumatic Diseases.Current rheumatology reports · 2023Review
- Review
- Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.Annals of medicine · 2022Review
- Juvenile idiopathic arthritis.Nature reviews. Disease primers · 2022Review
- The Term "Juvenile Idiopathic Arthritis (JIA)" is Misleading. It Will not be Sufficient to Just Replace this Term.Pharmaceutical medicine · 2021Article
- Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study.Pediatric rheumatology online journal · 2019Observational
- Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era.Arthritis research & therapy · 2019Article
- Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2018Article
- Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment.Rheumatology international · 2018Article
- Clinical Trial Design in Juvenile Idiopathic Arthritis.Paediatric drugs · 2017Article
- Clinical outcome measures in juvenile idiopathic arthritis.Pediatric rheumatology online journal · 2016Review
- Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.Diabetes care · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatments available to children with juvenile idiopathic arthritis (JIA) have improved dramatically in the past 15 years, largely because of the development of powerful new biologic treatments. However, the seeds of this development were sewed over 40 years ago with the formation of a group of paediatric rheumatologists who understood the necessity of performing clinical trials in children with JIA. From there, international paediatric rheumatology networks have grown, and are dedicated to and highly experienced in performing such clinical trials. Development of validated outcomes and methodologies has also been critical. The ability to perform these trials stems from legislation enabling the FDA and the European Medicines Agency to require studies to be performed in children before they can be licensed for use in children. Current efforts to enhance the understanding of treatment options for patients with JIA include the development of disease-specific rather than drug-specific consolidated registries, studies in personalized predictive medicine and the development of treatment protocols for regular clinical care of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.